oral ROR_t inverse agonist
Ph. I in HV up to 200 mg w/ PD, discontinued
from HTS + opt.
Scientific Reports, May 26, 2021
Janssen R&D, La Jolla, CA
The Janssen RORgt inhibitor, JNJ-61803534, is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated PD. Unfortunately, development was terminated due to findings in…